The potential drug-drug interactions of midostaurin may impact the choice of antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate the incidence of invasive fungal diseases (IFD) during the treatment of FLT3-mutated AML patients and to correlate it to the different AF prophylaxis strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen patients treated with chemotherapy + midostaurin as induction/reinduction, consolidation or both were enrolled. During induction, the incidence of probable/proven and possible IFD was 10.5% and 9.7%, respectively; no statistically significant difference was observed according to the different AF strategy adopted. The median duration of neutropenia was similar in patients with or without IFD. Proven/probable and possible IFD incidence was 2.4% and 1.8%, respectively, during consolidation. Age was the only risk factor for IFD (OR, 95% CI, 1.10 [1.03–1.19]) and complete remission achievement after first induction the only one for survival (OR, 95% CI, 5.12 [1.93–13.60]). The rate of midostaurin discontinuation was similar across different AF strategies. The IFD attributable mortality during induction was 8.3%. In conclusion, the 20.2% overall incidence of IFD occurring in FLT3-mutated AML during induction with chemotherapy + midostaurin, regardless of AF strategy type, was noteworthy, and merits further study, particularly in elderly patients.

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study / Cattaneo, C.; Marchesi, F.; Terrenato, I.; Bonuomo, V.; Fracchiolla, N. S.; Delia, M.; Criscuolo, M.; Candoni, A.; Prezioso, L.; Facchinelli, D.; Pasciolla, C.; Del Principe, M. I.; Dargenio, M.; Buquicchio, C.; Mitra, M. E.; Farina, F.; Borlenghi, E.; Nadali, G.; Gagliardi, V. P.; Fianchi, L.; Sciume, M.; Menna, P.; Busca, A.; Rossi, G.; Pagano, L.. - In: JOURNAL OF FUNGI. - ISSN 2309-608X. - 8:6(2022), pp. 583-593. [10.3390/jof8060583]

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

Candoni A.;
2022

Abstract

The potential drug-drug interactions of midostaurin may impact the choice of antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate the incidence of invasive fungal diseases (IFD) during the treatment of FLT3-mutated AML patients and to correlate it to the different AF prophylaxis strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen patients treated with chemotherapy + midostaurin as induction/reinduction, consolidation or both were enrolled. During induction, the incidence of probable/proven and possible IFD was 10.5% and 9.7%, respectively; no statistically significant difference was observed according to the different AF strategy adopted. The median duration of neutropenia was similar in patients with or without IFD. Proven/probable and possible IFD incidence was 2.4% and 1.8%, respectively, during consolidation. Age was the only risk factor for IFD (OR, 95% CI, 1.10 [1.03–1.19]) and complete remission achievement after first induction the only one for survival (OR, 95% CI, 5.12 [1.93–13.60]). The rate of midostaurin discontinuation was similar across different AF strategies. The IFD attributable mortality during induction was 8.3%. In conclusion, the 20.2% overall incidence of IFD occurring in FLT3-mutated AML during induction with chemotherapy + midostaurin, regardless of AF strategy type, was noteworthy, and merits further study, particularly in elderly patients.
2022
8
6
583
593
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study / Cattaneo, C.; Marchesi, F.; Terrenato, I.; Bonuomo, V.; Fracchiolla, N. S.; Delia, M.; Criscuolo, M.; Candoni, A.; Prezioso, L.; Facchinelli, D.; Pasciolla, C.; Del Principe, M. I.; Dargenio, M.; Buquicchio, C.; Mitra, M. E.; Farina, F.; Borlenghi, E.; Nadali, G.; Gagliardi, V. P.; Fianchi, L.; Sciume, M.; Menna, P.; Busca, A.; Rossi, G.; Pagano, L.. - In: JOURNAL OF FUNGI. - ISSN 2309-608X. - 8:6(2022), pp. 583-593. [10.3390/jof8060583]
Cattaneo, C.; Marchesi, F.; Terrenato, I.; Bonuomo, V.; Fracchiolla, N. S.; Delia, M.; Criscuolo, M.; Candoni, A.; Prezioso, L.; Facchinelli, D.; Pasc...espandi
File in questo prodotto:
File Dimensione Formato  
jof-08-00583-v2.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 716.23 kB
Formato Adobe PDF
716.23 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1294013
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact